| Literature DB >> 33745988 |
Abstract
Sex and gender differences in lung health and disease are imperative to consider and study if precision pulmonary medicine is to be achieved. The development of reliable COPD biomarkers has been elusive, and the translation of biomarkers to clinical care has been limited. Useful and effective biomarkers must be developed with attention to clinical heterogeneity of COPD; inherent heterogeneity exists related to grouping women and men together in the studies of COPD. Considering sex and gender differences and influences related to -omics may represent progress in susceptibility, diagnostic, prognostic, and therapeutic biomarker development and clinical innovation to improve the lung health of men and women.Entities:
Keywords: -omics; COPD; biomarkers; gender; precision medicine; sex
Mesh:
Substances:
Year: 2021 PMID: 33745988 PMCID: PMC8295903 DOI: 10.1016/j.chest.2021.03.024
Source DB: PubMed Journal: Chest ISSN: 0012-3692 Impact factor: 10.262